CIK 0000914475 · Large accelerated filer
NEUROCRINE BIOSCIENCES INC
Sign in to watch- Ticker
- NBIX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330525145
- Phone
- (858) 617-7600
- Business address
- 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,162,347
- in 4 filings, $3.2M under 10b5-1 plans
Net −$3,162,347. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-13 | Boyer David W. Chief Corp. Affairs Officer | Sale 10b5-1 | −955 | $133.10 | $127K | 5,751 |
| 2024-02-13 | Boyer David W. Chief Corp. Affairs Officer | Sale 10b5-1 | −856 | $133.05 | $114K | 4,895 |
| 2024-02-13 | Boyer David W. Chief Corp. Affairs Officer | Grant or award · Stock Option 10b5-1 | +30,977 | 30,977 | ||
| 2024-02-13 | Boyer David W. Chief Corp. Affairs Officer | Grant or award · Restricted Stock Unit 10b5-1 | +6,165 | 6,165 | ||
| 2024-02-13 | BENEVICH ERIC Chief Commercial Officer | Sale 10b5-1 | −1,098 | $133.01 | $146K | 40,616 |
| 2024-02-13 | BENEVICH ERIC Chief Commercial Officer | Grant or award · Stock Option 10b5-1 | +39,426 | 39,426 | ||
| 2024-02-13 | BENEVICH ERIC Chief Commercial Officer | Grant or award · Restricted Stock Unit 10b5-1 | +7,846 | 7,846 | ||
| 2024-02-13 | ABERNETHY MATT Chief Financial Officer | Sale 10b5-1 | −1,352 | $132.85 | $180K | 31,528 |
| 2024-02-13 | ABERNETHY MATT Chief Financial Officer | Grant or award · Stock Option 10b5-1 | +45,058 | 45,058 | ||
| 2024-02-13 | ABERNETHY MATT Chief Financial Officer | Grant or award · Restricted Stock Unit 10b5-1 | +8,966 | 8,966 | ||
| 2024-02-13 | GORMAN KEVIN CHARLES Chief Executive Officer | Option exercise | +2,778 | $35.99 | $100K | 509,740 |
| 2024-02-13 | GORMAN KEVIN CHARLES Chief Executive Officer | Option exercise | +2,312 | $43.24 | $100K | 512,052 |
| 2024-02-13 | GORMAN KEVIN CHARLES Chief Executive Officer | Option exercise · Incentive Stock Option | −2,778 | $35.99 | $100K | 0 |
| 2024-02-13 | GORMAN KEVIN CHARLES Chief Executive Officer | Option exercise · Incentive Stock Option | −2,312 | $43.24 | $100K | 0 |
| 2024-02-08 | Boyer David W. Chief Corp. Affairs Officer | Sale 10b5-1 | −700 | $134.19 | $94K | 5,523 |
| 2024-02-08 | Boyer David W. Chief Corp. Affairs Officer | Sale 10b5-1 | −628 | $136.78 | $86K | 4,895 |
| 2024-02-08 | Cooke Julie Chief Human Resources Officer | Sale 10b5-1 | −700 | $134.23 | $94K | 17,892 |
| 2024-02-08 | Cooke Julie Chief Human Resources Officer | Sale 10b5-1 | −629 | $136.78 | $86K | 17,263 |
| 2024-02-08 | ROBERTS EIRY Chief Medical Officer | Sale 10b5-1 | −980 | $134.21 | $132K | 22,717 |
| 2024-02-08 | Lippoldt Darin Chief Legal Officer | Sale 10b5-1 | −911 | $134.24 | $122K | 38,755 |
Page 38 of 49 · 963 trades